Raf激酶抑制蛋白在常见消化系统恶性肿瘤中的研究进展  

Anvances in research on Raf kinase inhibitory protein in common digestive system malignant tumors

作　　者：喻敏[1] 吕农华[1] 

机构地区：[1]南昌大学第一附属医院消化内科,江西南昌330006

出　　处：《肿瘤》2013年第4期378-381,共4页Tumor

摘　　要：Raf激酶抑制蛋白(Rafkinase inhibitory protein,RKIP)是磷脂酰乙醇胺结合蛋白(phosphatidylethanolamine-binding protein,PEBP)家族的成员之一,其在丝裂原活化蛋白激酶(mitogen-activated protein kinases,MAPK)、G蛋白偶联受体(G protein-coupled-receptors,GRCP)及核因子-κB(nuclear factor-kappaB,NF-κB)等蛋白激酶信号转导通路中起着重要的调节作用。近年来,在前列腺癌、乳腺癌及黑素瘤等多种恶性肿瘤中均发现RKIP表达下调或缺失,并可能通过抑制细胞侵袭和肿瘤新生血管形成等方式抑制肿瘤转移。同时有多项研究证实,RKIP作为一个肿瘤转移抑制基因,参与抑制了多种消化系统恶性肿瘤的转移,使其成为消化系统肿瘤防治研究的一个新靶点。本文就RKIP在常见消化系统恶性肿瘤中的研究进展作一综述。RKIP （Raf kinase inhibitor protein） is a member of PEBP （phosphatidylethanolamine-binding protein） family, which plays a pivotal modulatory role in MAPK （mitogen-activated protein kinase）, GPCR （G-protein-coupled receptor） and NF-KB （ nuclear factor-kappaB） signaling transduction pathways. In recent years, many studies reported that RKIP expression is weakened or lost in a series of malignant tumors such as prostate cancer, breast cancer and melanoma. RKIP may also play an important role in inhibition of tumor metastasis via inhibition of cell invasion and tumor angiogenesis. Recently, many experiments revealed that RKIP which is a metastasis-suppressor gene participates in the suppression of metastasis in a variety of digestive system malignant tumors and it will become a new target for prevention and control of digestive system cancer. In this article, the advances of research on RKIP in common digestive system malignant tumors were reviewed.

关 键 词：消化系统肿瘤 MAP激酶信号系统 Raf激酶类 磷脂酰乙醇胺结合蛋白质 

分 类 号：R735[医药卫生—肿瘤]